Dashboard
Manage Tickers

MNMD Mind Medicine (MindMed) Inc.

Nasdaq mindmed.co


$ 11.73 $ -0.51 (-4.2 %)    

Thursday, 13-Nov-2025 18:12:02 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 608.60 $ -12.68 (-2.04 %)
DIA $ 475.40 $ -8.02 (-1.66 %)
SPY $ 672.50 $ -11.34 (-1.66 %)
TLT $ 89.42 $ -0.74 (-0.82 %)
GLD $ 384.50 $ -3.12 (-0.81 %)
$ 11.63
$ 11.93
$ 11.63 x 25
$ 11.92 x 20
$ 11.61 - $ 12.42
$ 4.70 - $ 14.43
1,781,389
na
1.2B
$ 2.01
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 07-31-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-06-2025 01-01-1970 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-08-2024 03-31-2024 10-Q
8 02-28-2024 12-31-2023 10-K
9 11-02-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 03-09-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-16-2022 03-31-2022 10-Q
16 03-28-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

canaccord-genuity-maintains-buy-on-mind-medicine-raises-price-target-to-25
Canaccord Genuity Maintains Buy on Mind Me...
11/07/2025 21:51:24

Canaccord Genuity analyst Sumant Kulkarni maintains Mind Medicine (NASDAQ:MNMD) with a Buy and raises the price target from ...

rbc-capital-maintains-outperform-on-mind-medicine-lowers-price-target-to-20
RBC Capital Maintains Outperform on Mind M...
11/07/2025 19:13:54

RBC Capital analyst Brian Abrahams maintains Mind Medicine (NASDAQ:MNMD) with a Outperform and lowers the price target from ...

mind-medicine-q3-eps-078-misses-050-estimate
Mind Medicine Q3 EPS $(0.78) Misses $(0.50...
11/06/2025 21:04:51

Mind Medicine (NASDAQ:MNMD) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.5...

earnings-scheduled-for-november-6-2025
Earnings Scheduled For November 6, 2025
11/06/2025 11:12:19

reported-earlier-mindmed-prices-225m-public-offering-of-18375m-shares-at-1225-each-to-fund-rd-and-corporate-growth
Reported Earlier, MindMed Prices $225M Pub...
10/30/2025 08:10:49

mind-medicine-announces-proposed-public-offering-amount-not-disclosed
Mind Medicine Announces Proposed Public Of...
10/29/2025 20:02:20

mind-medicine-analyst-cites-strong-phase-3-pipeline-for-anxiety-depression
Mind Medicine Analyst Cites Strong Phase 3...
10/13/2025 18:54:39

Needham starts MindMed at Buy with a $28 target, citing strong Phase 3 prospects for MM120 in anxiety and depression and solid ...

Core News & Articles
'Psychedelics Show Promise As An 'Entirely...
10/13/2025 17:28:47

https://www.marijuanamoment.net/psychedelics-show-promise-as-an-entirely-new-type-of-anti-inflammatory-treatment-research-sugge...

needham-initiates-coverage-on-mind-medicine-with-buy-rating-announces-price-target-of-28
Needham Initiates Coverage On Mind Medicin...
10/13/2025 10:06:25

Needham analyst Ami Fadia initiates coverage on Mind Medicine (NASDAQ:MNMD) with a Buy rating and announces Price Target of ...

the-insider-report-panic-never-pays
The Insider Report: Panic Never Pays
10/11/2025 21:32:55

Core News & Articles
'New York Lawmakers Hold Hearing Psilocybi...
10/02/2025 15:03:14

https://www.marijuanamoment.net/new-york-lawmakers-hold-hearing-psilocybins-medical-benefits-amid-broader-debate-over-psychedel...

mindmed-study-finds-nearly-half-of-adults-with-severe-anxiety-report-suicidal-thoughts-almost-every-day
MindMed Study Finds Nearly Half Of Adults ...
09/19/2025 11:02:11

Researchers from Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a late-stage clinica...

Core News & Articles
'Massachusetts Lawmakers Approve Bill To C...
09/12/2025 16:30:15

https://www.marijuanamoment.net/massachusetts-lawmakers-approve-bill-to-create-psychedelic-therapy-pilot-program/

mindmed-publishes-phase-2b-mm120-lsd-results-in-jama-demonstrating-statistically-significant-and-sustained-anxiety-reduction-in-gad-patients-100-g-dose-achieved-65-response-48-remission-at-week-12-supporting-ongoing-phase-3-trials-and-fda-breakthrough-therapy-designation
MindMed Publishes Phase 2b MM120 (LSD) Res...
09/04/2025 15:15:55

The Phase 2b study demonstrated a statistically significant dose-response relationship at the primary endpoint following a sing...

Core News & Articles
'Military To Start Testing Service Members...
08/28/2025 18:16:26

https://www.marijuanamoment.net/military-to-start-testing-service-members-for-the-psychedelic-psilocin-memo-shows/

Core News & Articles
'GOP Senator Is 'Confident' Psychedelics A...
08/22/2025 19:53:09

https://www.marijuanamoment.net/gop-senator-is-confident-psychedelics-access-will-expand-under-trump-saying-many-veterans-speak...

Core News & Articles
'U.S. Senate Committee To Hold Hearing On ...
08/21/2025 18:35:07

https://www.marijuanamoment.net/u-s-senate-committee-to-hold-hearing-on-benefits-of-psychedelics-for-military-veterans/

oppenheimer-reinstates-outperform-on-mind-medicine-announces-25-price-target
Oppenheimer Reinstates Outperform on Mind ...
08/04/2025 12:51:47

Oppenheimer analyst Jay Olson reinstates Mind Medicine (NASDAQ:MNMD) with a Outperform and announces $25 price target.

chardan-capital-maintains-buy-on-mind-medicine-maintains-20-price-target
Chardan Capital Maintains Buy on Mind Medi...
08/01/2025 11:36:16

Chardan Capital analyst Rudy Li maintains Mind Medicine (NASDAQ:MNMD) with a Buy and maintains $20 price target.

mind-medicine-q2-eps-050-misses-037-estimate
Mind Medicine Q2 EPS $(0.50) Misses $(0.37...
07/31/2025 20:02:06

Mind Medicine (NASDAQ:MNMD) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.3...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION